• Users Online: 199
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 11  |  Issue : 2  |  Page : 74-76

The use of carfilzomib to treat extramedullary plasmacytoma and review of the literature

Department of Hematology, Baskent University School of Medicine, Istanbul, Turkey

Correspondence Address:
Dr. Figen Atalay
Oymac. Sk. No. 7 Altunizade, Uskudar, Istanbul
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/joah.joah_83_19

Rights and Permissions

A 61-year-old woman was diagnosed with multiple myeloma (MM) (immunoglobulin G kappa type) in 2012. A bortezomib-based chemotherapy protocol was administered to the patient, and the patient underwent an autologous transplant. During lenalidomide maintenance therapy, she presented with anemia and extramedullary plasmacytomas (EMPs) with no bone marrow infiltration by clonal plasma cells. Her disease was in complete remission after six cycles of the carfilzomib-dexamethasone (KD) protocol. EMPs are seen in MM patients at the time of diagnosis or relapse. There is a challenge related to these patients' treatment schedules, as no consensus or standard treatment protocol has yet been defined. In this article, we present a case regarding the presentation of EMP relapse in a myeloma patient who is in remission after long-term carfilzomib therapy. We demonstrate that a KD treatment may be effective in patients with EMPs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded166    
    Comments [Add]    
    Cited by others 2    

Recommend this journal